A Phase 3 interventional study of Intravitreal Bevacizumab in Angioid Streaks and Choroidal Neovascularization, sponsored by Asociación para Evitar la Ceguera en México. Terminated at 1 site in Mexico. Per ClinicalTrials.gov, last updated 2024-06-03.
Sponsored by Asociación para Evitar la Ceguera en México · Phase 3, Interventional, and Treatment
Among 14 studies testing bevacizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Bevacizumab · Choroidal Neovascularization.
Among the 14 studies testing bevacizumab in Choroidal Neovascularization, this one is one of 4 that started in 2005, is one of 6 in phase 3, and was the 2nd registered.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →None of the 14 studies testing bevacizumab in Choroidal Neovascularization is open now.
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 6 Choroidal Neovascularization studies recruiting now, 4 (67%) set no upper age limit and 0 (0%) stop at 75 or younger; 0 take children under 18; 0 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2005.
Median enrollment 25 across the 12 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
1 of 14 have an industry lead sponsor. The 10 most frequent:
Asociación para Evitar la Ceguera en México is the lead sponsor of 60 studies on the registry; 6 are open to participants now.
Asociación para Evitar la Ceguera en México has 3 studies filed under Choroidal Neovascularization — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing bevacizumab in Choroidal Neovascularization, from their registry updates:
Nothing recorded among them since 2026-09-25.
Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks
A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
BCVA
Fluoresceine Angiography
Optical Coherence Tomography
This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevacizumab
Choroidal Neovascularization →
Asociación para Evitar la Ceguera en México